HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Rifamycins

A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei.
Also Known As:
Rifomycins
Networked: 71 relevant articles (6 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Sharma, Surendra K: 3 articles (03/2014 - 01/2013)
2. Tharyan, Prathap: 3 articles (03/2014 - 01/2013)
3. Kadhiravan, Tamilarasu: 3 articles (03/2014 - 01/2013)
4. Chaisson, Richard E: 2 articles (10/2015 - 10/2003)
5. Sharma, Anju: 2 articles (03/2014 - 01/2013)
6. Boffito, Marta: 2 articles (01/2014 - 11/2008)
7. Karakousis, Petros C: 2 articles (12/2012 - 07/2012)
8. Peloquin, Charles A: 2 articles (07/2012 - 11/2009)
9. Pozniak, Anton: 2 articles (04/2009 - 11/2008)
10. Murphy, Christopher K: 2 articles (09/2007 - 12/2006)

Related Diseases

1. Infection
09/01/2007 - "This enhanced antibacterial activity, along with their potential lack of drug-drug interactions, are considerations that suggest the potential of these novel rifamycins in combination therapy to treat serious Gram-positive infections."
03/01/2005 - "Although rifamycins have excellent activity against Chlamydophila pneumoniae and Chlamydia trachomatis in vitro, concerns about the possible development of resistance during therapy have discouraged their use for treatment of chlamydial infections. "
10/01/2003 - "Treatment of chronic infections with rifamycins: is resistance likely to follow?"
09/03/2002 - "Major changes since the last edition of the guidelines include 1) updated recommendations for discontinuing primary and secondary OI prophylaxis among persons whose CD4+ T lymphocyte counts have increased in response to antiretroviral therapy; 2) emphasis on screening all HIV-infected persons for infection with hepatitis C virus; 3) new information regarding transmission of human herpesvirus 8 infection; 4) new information regarding drug interactions, chiefly related to rifamycins and antiretroviral drugs; and 5) revised recommendations for immunizing HIV-infected adults and adolescents and HIV-exposed or infected children."
06/14/2002 - "Major changes since the last edition of the guidelines include 1) updated recommendations for discontinuing primary and secondary OI prophylaxis among persons whose CD4+ T lymphocyte counts have increased in response to antiretroviral therapy; 2) emphasis on screening all HIV-infected persons for infection with hepatitis C virus; 3) new information regarding transmission of human herpesvirus 8 infection; 4) new information regarding drug interactions, chiefly related to rifamycins and antiretroviral drugs; and 5) revised recommendations for immunizing HIV-infected adults and adolescents and HIV-exposed or infected children."
2. Tuberculosis (Tuberculoses)
3. Bacteremia
4. Bacterial Infections (Bacterial Infection)
5. Acquired Immunodeficiency Syndrome (AIDS)

Related Drugs and Biologics

1. Rifampin (Rifampicin)
2. Rifabutin (Ansamycin)
3. rifapentine (Priftin)
4. rifamycin SV
5. Anti-Bacterial Agents (Antibiotics)
6. Macrolides
7. Clarithromycin (Biaxin)
8. FCE 22807
9. Azithromycin (Zithromax)
10. Quinolones

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Transplants (Transplant)
3. Highly Active Antiretroviral Therapy (HAART)
4. Transplantation (Transplant Recipients)
5. Art Therapy